A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

In just a few weeks, you will have a special opportunity to rediscover downtown La Grange and support a good cause.

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis from Ovarian Cancer Research ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.